AXIOS August 28, 2024
Adriel Bettelheim

Pfizer on Tuesday became the latest major drugmaker to sell medicine directly to consumers, launching a digital platform that’s initially directed at people with migraines and respiratory ailments, including COVID-19.

Why it matters: The move puts Pfizer in competition with Eli Lilly, which in January launched its own D2C platform to provide prescriptions for conditions like obesity, migraines, and diabetes.

  • The new portal could stir up more business for Pfizer drugs, though the company said patients won’t be steered to its products and that decisions will remain with physicians.

Driving the news: The PfizerForAll platform leverages partnerships with telehealth provider UpScriptHealth, online pharmacy Alto Pharmacy, and the grocery delivery service Instacart.

  • It offers $35 virtual appointments with...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Digital Health, Patient / Consumer, Pharma, Pharma / Biotech, Technology, Telehealth
Bariatric Surgeons Being Put Out of Work by GLP-1 Drugs
The CMS NHE 2023 Report: An Incomplete Picture at a Pivotal Time
Pharma At A Crossroads: Navigating Cost Pressures And Regulatory Shifts In 2025
Why Walgreens Is Reportedly Considering a Private Equity Buyer
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease

Share This Article